130 related articles for article (PubMed ID: 31780055)
21. Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer.
Guo Z; Chen X; Du T; Zhu D; Lai Y; Dong W; Wu W; Lin C; Liu L; Huang H
Med Oncol; 2017 Jan; 34(1):13. PubMed ID: 28012134
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression.
Hu Y; Wu Q; Gao J; Zhang Y; Wang Y
BMC Urol; 2019 Jul; 19(1):67. PubMed ID: 31324239
[TBL] [Abstract][Full Text] [Related]
23.
Cai C; Luo J; Liu Q; Liu Z; Zhao Y; Wu X; Yuegao Y; Lei Y; Lu J; Wang Y; Cai Z; Duan X; Lei M; Gu D; Liu Y
Genet Test Mol Biomarkers; 2021 Feb; 25(2):131-139. PubMed ID: 33596143
[No Abstract] [Full Text] [Related]
24. SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy.
Li F; Xu Y; Liu RL
Int Urol Nephrol; 2019 Mar; 51(3):443-451. PubMed ID: 30739268
[TBL] [Abstract][Full Text] [Related]
25. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of NUCB2 mRNA expression in prostate cancer.
Zhang H; Qi C; Li L; Luo F; Xu Y
J Exp Clin Cancer Res; 2013 Aug; 32(1):56. PubMed ID: 23958433
[TBL] [Abstract][Full Text] [Related]
27. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.
Hou H; Chen W; Zhao L; Zuo Q; Zhang G; Zhang X; Wang H; Gong H; Li X; Wang M; Wang Y; Li X
J Clin Pathol; 2012 Dec; 65(12):1088-96. PubMed ID: 22944623
[TBL] [Abstract][Full Text] [Related]
28. XPNPEP2 is associated with lymph node metastasis in prostate cancer patients.
Li F; Dai Y; Xu H; Huang K; Zhou Y; Luo D; Ma D; Xi L; Lv M; Ma X
Sci Rep; 2019 Jul; 9(1):10078. PubMed ID: 31296901
[TBL] [Abstract][Full Text] [Related]
29. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
30. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.
Wan Y; Zeng ZC; Xi M; Wan S; Hua W; Liu YL; Zhou YL; Luo HW; Jiang FN; Zhong WD
Hum Pathol; 2015 Feb; 46(2):295-303. PubMed ID: 25532941
[TBL] [Abstract][Full Text] [Related]
31. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
32. Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis.
Huang W; Eickhoff JC; Mehraein-Ghomi F; Church DR; Wilding G; Basu HS
Prostate; 2015 Aug; 75(11):1150-9. PubMed ID: 25893668
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
34. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.
Huang YQ; Han ZD; Liang YX; Lin ZY; Ling XH; Fu X; Cai C; Bi XC; Dai QS; Chen JH; He HC; Chen YR; Jiang FN; Zhong WD
Med Oncol; 2014 Jan; 31(1):820. PubMed ID: 24338276
[TBL] [Abstract][Full Text] [Related]
35. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.
Zhang M; Guan J; Huo YL; Song YS; Chen LZ
Asian J Androl; 2019; 21(4):387-392. PubMed ID: 30860083
[TBL] [Abstract][Full Text] [Related]
37. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
38. C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance.
Meng J; Wang LH; Zou CL; Dai SM; Zhang J; Lu Y
Med Sci Monit; 2017 Oct; 23():5176-5183. PubMed ID: 29084195
[TBL] [Abstract][Full Text] [Related]
39. High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer.
Zhang H; Qi C; Wang A; Li L; Xu Y
Tumour Biol; 2014 Mar; 35(3):2025-8. PubMed ID: 24092574
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of CXCR7 Is Associated with Poor Prognosis of Prostate Cancer.
Yang J; Tang H; Huang J; An H
Med Sci Monit; 2018 Jul; 24():5185-5191. PubMed ID: 30047547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
